Sage Therapeutics Dirección

Dirección controles de criterios 2/4

El CEO de Sage Therapeutics' es Barry Greene , nombrado en Dec 2020, tiene una permanencia de 3.5 años. compensación anual total es $6.24M, compuesta por 12.8% salario y 87.2% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.078% de las acciones de la empresa, por valor de $529.04K. La antigüedad media del equipo directivo y de la junta directiva es de 3.6 años y 8.8 años, respectivamente.

Información clave

Barry Greene

Chief Executive Officer (CEO)

US$6.2m

Compensación total

Porcentaje del salario del CEO	12.8%
Permanencia del CEO	3.6yrs
Participación del CEO	0.08%
Permanencia media de la dirección	3.7yrs
Promedio de permanencia en la Junta Directiva	8.9yrs

Actualizaciones recientes de la dirección

Recent updates

Sage Therapeutics Stock: Remains A Hold On Upcoming Essential Tremor Treatment Data

May 30

Is Sage Therapeutics (NASDAQ:SAGE) In A Good Position To Invest In Growth?

May 21

Analysts Have Just Cut Their Sage Therapeutics, Inc. (NASDAQ:SAGE) Revenue Estimates By 50%

Feb 22

Calculating The Fair Value Of Sage Therapeutics, Inc. (NASDAQ:SAGE)

Feb 15

Sizing Up Sage Therapeutics

Jan 22

Things Look Grim For Sage Therapeutics, Inc. (NASDAQ:SAGE) After Today's Downgrade

Aug 09

Here's Why We're Not Too Worried About Sage Therapeutics' (NASDAQ:SAGE) Cash Burn Situation

Feb 22

An Intrinsic Calculation For Sage Therapeutics, Inc. (NASDAQ:SAGE) Suggests It's 45% Undervalued

Nov 12

Here's Why We're Not Too Worried About Sage Therapeutics' (NASDAQ:SAGE) Cash Burn Situation

Oct 14

Sage Therapeutics GAAP EPS of -$2.13 beats by $0.02, revenue of $1.5M misses by $0.27M

Aug 02

What You Need To Know About The Sage Therapeutics, Inc. (NASDAQ:SAGE) Analyst Downgrade Today

Aug 05

Sage Therapeutics: Showing Upside, But There Are Plenty Of Unknowns

Jul 25

Sage Therapeutics Needs To Show Improved Data To Regain Investor Trust

Jul 12

Sage Therapeutics Q1 2021 Earnings Preview

May 03

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Barry Greene en comparación con los beneficios de Sage Therapeutics?
Fecha	Compensación total	Salario	Ingresos de la empresa
Mar 31 2024	n/a	n/a	-US$503m
Dec 31 2023	US$6m	US$799k	-US$541m
Sep 30 2023	n/a	n/a	-US$656m
Jun 30 2023	n/a	n/a	-US$592m
Mar 31 2023	n/a	n/a	-US$558m
Dec 31 2022	US$6m	US$761k	-US$533m
Sep 30 2022	n/a	n/a	-US$510m
Jun 30 2022	n/a	n/a	-US$503m
Mar 31 2022	n/a	n/a	-US$484m
Dec 31 2021	US$59m	US$735k	-US$458m
Sep 30 2021	n/a	n/a	US$642m
Jun 30 2021	n/a	n/a	US$666m
Mar 31 2021	n/a	n/a	US$637m
Dec 31 2020	US$836k	US$53k	US$606m

Compensación vs. Mercado: La compensación total de Barry($USD6.24M) está por encima de la media de empresas de tamaño similar en el mercado US ($USD3.39M).

Compensación vs. Ingresos: La compensación de Barry ha aumentado mientras la empresa no es rentable.

CEO

Barry Greene (61 yo)

3.6yrs

Permanencia

US$6,237,491

Compensación

Mr. Barry E. Greene serves as President and Chief Executive Officer at Sage Therapeutics, Inc. since December 15, 2020 and its Director since October 1, 2020. Mr. Greene joined the Sage Therapeutics, Inc....

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Barry Greene	President	3.6yrs	US$6.24m	0.078% $ 498.5k
Kimi Iguchi	CFO & Treasurer	11.3yrs	US$1.98m	0.12% $ 748.0k
Anne Cook	Senior VP	8.8yrs	US$2.15m	0.023% $ 148.0k
Christopher Benecchi	Chief Business Officer	2.8yrs	US$2.28m	0.0098% $ 63.0k
Laura Gault	Chief Medical Officer	1.8yrs	US$1.27m	0.00038% $ 2.4k
Matt Lasmanis	Chief Technology & Innovation Officer	3.7yrs	sin datos	sin datos
Mike Quirk	Chief Scientific Officer	less than a year	sin datos	sin datos
Ashley Kaplowitz	Director of Investor Relations	no data	sin datos	sin datos
Erin Lanciani	Chief People & Experience Officer	no data	sin datos	sin datos
Amy Schacterle	Senior Vice President of R&D Strategy and Business Management	7.3yrs	sin datos	sin datos
Heinrich Schlieker	Senior Vice President of Technical Operations	3.7yrs	sin datos	sin datos
Helen Colquhoun	Senior Vice President of Drug Safety & Pharmacovigilance	no data	sin datos	sin datos

3.7yrs

Permanencia media

58yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de SAGE se considera experimentado (3.4 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Barry Greene	President	3.8yrs	US$6.24m	0.078% $ 498.5k
Michael Cola	Independent Director	9.8yrs	US$440.05k	0% $ 0
James Frates	Independent Director	10.2yrs	US$435.05k	0.0047% $ 30.2k
David Farb	Member of Scientific Advisory Board	no data	sin datos	sin datos
Geno Germano	Independent Chair of the Board	8yrs	US$417.55k	0% $ 0
Michael Rogawski	Member of Scientific Advisory Board	no data	sin datos	sin datos
James Audia	Member of Scientific Advisory Board	no data	sin datos	sin datos
Christine Marx	Member of Scientific Advisory Board	no data	sin datos	sin datos
A. Morrow	Member of Scientific Advisory Board	no data	sin datos	sin datos
Stephen Moss	Member of Scientific Advisory Board	no data	sin datos	sin datos
Scott Runyon	Member of Scientific Advisory Board	no data	sin datos	sin datos
Donald Stein	Member of Scientific Advisory Board	no data	sin datos	sin datos

8.9yrs

Permanencia media

63yo

Promedio de edad

Junta con experiencia: La junta directiva de SAGE se considera experimentada (8.8 años de antigüedad promedio).

Sage Therapeutics Dirección

Dirección controles de criterios 2/4

Información clave

Actualizaciones recientes de la dirección

Sage Therapeutics, Inc., Annual General Meeting, Jun 10, 2024

Sage Therapeutics, Inc. Announces Changes to Board of Directors

Insufficient new directors

Insider recently bought US$51k worth of stock

President recently bought US$500k worth of stock

Sage Therapeutics, Inc. Announces Resignation of Jeffrey M. Jonas as Chief Innovation Officer

Recent updates

Sage Therapeutics, Inc.(NasdaqGM:SAGE) dropped from Russell 2500 Growth Index

Sage Therapeutics, Inc. Announces Topline Results from the Phase 2 SURVEYOR Study

Sage Therapeutics Stock: Remains A Hold On Upcoming Essential Tremor Treatment Data

Is Sage Therapeutics (NASDAQ:SAGE) In A Good Position To Invest In Growth?

Consensus revenue estimates increase by 32%, EPS downgraded

Sage Therapeutics, Inc., Annual General Meeting, Jun 10, 2024

First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Price target decreased by 13% to US$24.39

Sage Therapeutics, Inc. Announces Topline Results from Phase 2 PRECEDENT Study of DalzanemDor (SAGE-718) in the Treatment of Mild Cognitive Impairment in Parkinson's Disease

Sage Therapeutics, Inc. to Report Q1, 2024 Results on Apr 25, 2024

Analysts Have Just Cut Their Sage Therapeutics, Inc. (NASDAQ:SAGE) Revenue Estimates By 50%

Consensus revenue estimates fall by 50%

Consensus revenue estimates fall by 50%

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Calculating The Fair Value Of Sage Therapeutics, Inc. (NASDAQ:SAGE)

Sage Therapeutics, Inc. to Report Q4, 2023 Results on Feb 14, 2024

Sizing Up Sage Therapeutics

Price target decreased by 13% to US$21.94

Sage Therapeutics, Inc. Announces Changes to Board of Directors

Sage Therapeutics, Inc. and Biogen Inc. Announces ZURZUVAE (Zuranolone) 50 mg (Two 25 mg Capsules Per Day) CIV

Insufficient new directors

Sage Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $250 million.

Sage Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $250 million.

Sage Therapeutics, Inc. to Report Q3, 2023 Results on Nov 07, 2023

Sage Therapeutics, Inc. Announces U.S. Food and Drug Administration Granted Sage-718 Orphan Drug Designation for the Treatment of Huntington's Disease

Sage Therapeutics, Inc. Announces Reduction of the Workforce by Approximately 40%

Consensus revenue estimates fall by 57%

Things Look Grim For Sage Therapeutics, Inc. (NASDAQ:SAGE) After Today's Downgrade

New major risk - Share price stability

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Price target decreased by 21% to US$48.06

Sage Therapeutics, Inc. to Report Q2, 2023 Results on Aug 07, 2023

Insider recently bought US$51k worth of stock

Consensus revenue estimates increase by 14%

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Here's Why We're Not Too Worried About Sage Therapeutics' (NASDAQ:SAGE) Cash Burn Situation

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Biogen Inc. and Sage Therapeutics, Inc. Announce FDA Accepts Filing of New Drug Application and Grants Priority Review of Zuranolone in the Treatment of Major Depressive Disorder and Postpartum Depression

Sage Therapeutics, Inc. to Report Q4, 2022 Results on Feb 16, 2023

Sage Therapeutics and Biogen Complete Rolling Submission of New Drug Application for Zuranolone in the Treatment of Major Depressive Disorder and Postpartum Depression

President recently bought US$500k worth of stock

An Intrinsic Calculation For Sage Therapeutics, Inc. (NASDAQ:SAGE) Suggests It's 45% Undervalued

Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Sage Therapeutics, Inc. Announces Resignation of Jeffrey M. Jonas as Chief Innovation Officer

Sage Therapeutics Appoints Laura M. Gault as Chief Medical Officer

Sage Therapeutics, Inc. to Report Q3, 2022 Results on Nov 08, 2022

Sage Therapeutics and Biogen Present Further Analyses from Phase 3 Skylark Study of Zuranolone in Postpartum Depression At the European College of Neuropsychopharmacology (Ecnp) Congress

Here's Why We're Not Too Worried About Sage Therapeutics' (NASDAQ:SAGE) Cash Burn Situation

Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Sage Therapeutics GAAP EPS of -$2.13 beats by $0.02, revenue of $1.5M misses by $0.27M

Sage Therapeutics, Inc. Enters into Settlement Agreement

Sage Therapeutics, Inc.(NasdaqGM:SAGE) dropped from Russell 1000 Dynamic Index

We're Hopeful That Sage Therapeutics (NASDAQ:SAGE) Will Use Its Cash Wisely

Sage Therapeutics, Inc. Provides Zuranolone New Drug Application Update

Sage Therapeutics and Biogen Announce that the Phase 3 SKYLARK Study of Zuranolone in Postpartum Depression Met its Primary and All Key Secondary Endpoints

Consensus revenue estimates fall by 62%

Insider recently bought US$252k worth of stock

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Sage Therapeutics and Biogen Initiate Rolling Submission of New Drug Application (NDA) to U.S. Food and Drug Administration for Zuranolone for the Potential Treatment of Major Depressive Disorder (MDD)

Sage Therapeutics, Inc. to Report Q1, 2022 Results on May 03, 2022

Sage Therapeutics Announces Presentation of Promising Results from the Phase 2 Luminary Study of Sage-718 in Patients with Mild Cognitive Impairment and Mild Dementia Due to Alzheimer’s Disease

Sage Therapeutics: Well-Funded But Uninspiring Data

Consensus revenue estimates fall by 58%

We're Hopeful That Sage Therapeutics (NASDAQ:SAGE) Will Use Its Cash Wisely

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

Sage Therapeutics, Inc. Provides Business Update

Price target decreased to US$67.60

Sage Therapeutics, Inc and Biogen Inc Announce Phase 3 CORAL Study Met its Primary and Key Secondary Endpoints

Investor sentiment deteriorated over the past week